PROK Earnings & Financial Statements
ProKidney Corp.
$1.61
+$0.04(+2.55%)
23
Overall
40
Value
10
Tech
21
Quality
Market Cap
$474.65M
Volume
571.00K
52W Range
$1.30 - $3.48
Target Price
$5.50
PROK earnings and financial statements: ProKidney Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PROK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $893.0K | $76.0K | - | - | - |
| Operating income | -$165.01M | -$183.68M | -$151.52M | -$153.01M | -$55.11M |
| EBITDA | -$144.62M | -$158.49M | -$125.59M | -$143.99M | -$53.12M |
| Net income | -$68.99M | -$61.19M | -$35.47M | -$108.03M | -$55.15M |
| EPS (diluted) | $-0.52 | - | - | $-0.23 | $-0.22 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $335.57M | $441.07M | $420.55M | $518.00M | $40.30M |
| Total liabilities | $34.78M | $39.44M | $29.22M | $13.06M | $13.38M |
| Shareholders’ equity | -$1.01B | -$994.95M | -$1.10B | -$1.10B | $26.92M |
| Cash and equivalents | $108.54M | $99.12M | $60.65M | $490.25M | $20.56M |
| Long-term debt | - | $2.47M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$120.12M | -$126.35M | -$90.07M | -$77.09M | -$50.30M |
| Capital expenditure | $3.02M | -$29.51M | -$34.20M | -$1.85M | -$5.19M |
| Free cash flow | -$135.31M | -$155.86M | -$124.27M | -$78.94M | -$55.49M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROK | $1.61 | +2.5% | 571.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |